Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUAN P LOY

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1457493157
CMS profile
111725
Location
MARGATE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,147.48

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,117.48 71
Gift $30.00 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUAN P LOY

NPI 1457493157 · CMS profile ID 111725

Allopathic & Osteopathic Physicians / Internal Medicine

MARGATE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457493157?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUAN P LOY, NPI 1457493157, CMS profile ID 111725. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457493157?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JUAN P LOY, NPI 1457493157, CMS profile ID 111725. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457493157?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JUAN P LOY, NPI 1457493157, CMS profile ID 111725, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1457493157?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $1,147.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–73 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $14.4705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167677 CMS
AbbVie Inc. $17.9505/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795397361 CMS
Janssen Pharmaceuticals, Inc $23.9905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788263180 CMS
Amgen Inc. $13.0505/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826369733 CMS
Novo Nordisk Inc $19.0205/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811467495 CMS
ASCEND Therapeutics US, LLC $18.0005/19/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828479983 CMS
GlaxoSmithKline, LLC. $11.8605/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801657781 CMS
Novo Nordisk Inc $5.3405/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811467489 CMS
Novo Nordisk Inc $13.3205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811611243 CMS
Amgen Inc. $13.6705/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825478029 CMS
AbbVie Inc. $13.7505/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795397355 CMS
Lilly USA, LLC $15.3005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818580257 CMS
Radius Health, Inc. $12.8405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830745091 CMS
Lilly USA, LLC $12.7504/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818588555 CMS
Novo Nordisk Inc $23.4404/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810791521 CMS
Horizon Therapeutics plc $13.5904/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797167675 CMS
Esperion Therapeutics, Inc. $16.9904/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838344219 CMS
Novo Nordisk Inc $2.4904/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811611237 CMS
ASCEND Therapeutics US, LLC $12.0004/01/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828479205 CMS
Amarin Pharma Inc. $21.0903/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815383815 CMS
Gilead Sciences, Inc. $15.6603/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848232849 CMS
Amgen Inc. $11.8803/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825478023 CMS
Amarin Pharma Inc. $14.2603/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815241399 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,065.76 66
PY2020 $109.77 6
PY2021 $1,147.48 73
PY2022 $753.53 42
PY2023 $908.68 51
PY2024 $367.36 18
PY2025 $479.02 23

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,011,660.74 22
PY2024 Recipient $42,173.00 4
PY2024 Principal investigator $854,343.25 17
PY2023 Recipient $1,605.02 4
PY2023 Principal investigator $674,969.80 14
PY2022 Recipient $6,438.00 2
PY2022 Principal investigator $759,050.70 24
PY2021 Recipient $51.02 1
PY2021 Principal investigator $626,362.68 30
PY2020 Recipient $5,073.00 3
PY2020 Principal investigator $340,647.03 21
PY2019 Recipient $6,286.01 2
PY2019 Principal investigator $430,951.86 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,500.00 10/31/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEARCH INSTITUTE
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185548625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,436.00 08/13/2025 Non-covered Recipient Entity
South Florida Wellness and Clinical Research Institute LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215521950
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/16/2025 Non-covered Recipient Entity
South Florida Wellness and Clinical Research Institute LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215521940
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 07/16/2025 Non-covered Recipient Entity
South Florida Wellness and Clinical Research Institute LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215521942
Principal investigator 1 Alnylam Pharmaceuticals Inc. $846.00 07/16/2025 Non-covered Recipient Entity
South Florida Wellness and Clinical Research Institute LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215521944
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,436.00 07/16/2025 Non-covered Recipient Entity
South Florida Wellness and Clinical Research Institute LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215521946
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.80 07/16/2025 Non-covered Recipient Entity
South Florida Wellness and Clinical Research Institute LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215521948
Principal investigator 1 Eli Lilly and Company $2,077.95 07/15/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187891028
Principal investigator 1 Eli Lilly and Company $45.20 07/11/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187888096
Principal investigator 1 Amgen Inc. $54,851.63 06/08/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS & CLINICAL RESEARCH INSTITUTE, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648352
Principal investigator 1 Eli Lilly and Company $1,062.00 04/02/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187891026
Principal investigator 1 Eli Lilly and Company $734.46 03/10/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187891274
Principal investigator 1 Amgen Inc. $330,048.16 02/25/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS & CLINICAL RESEARCH INSTITUTE, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246648348
Principal investigator 1 Eli Lilly and Company $1,063.40 01/31/2025 Non-covered Recipient Entity
JEFFREY B ROSEN MD PA DBA CLINICAL RESEARCH OF SOUTH
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187883154
Principal investigator 1 Eli Lilly and Company $994.21 01/31/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187890894
Principal investigator 1 Eli Lilly and Company $5,005.14 01/27/2025 Non-covered Recipient Entity
JEFFREY B ROSEN MD PA DBA CLINICAL RESEARCH OF SOUTH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187883004
Principal investigator 1 Eli Lilly and Company $1,021.79 01/27/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187891344
Principal investigator 1 Eli Lilly and Company $42,664.00 01/21/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187888870
Principal investigator 1 Eli Lilly and Company $87,224.00 01/21/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187891340
Principal investigator 1 Eli Lilly and Company $141,264.00 01/07/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187888094
Principal investigator 1 Eli Lilly and Company $221,063.00 01/07/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187890892
Principal investigator 1 Eli Lilly and Company $93,733.00 01/07/2025 Non-covered Recipient Entity
SOUTH FLORIDA WELLNESS AND CLINICAL RESEAR
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187891342